Compare Moderna, Inc. (MRNA) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Redwire Corporation — how do they compare? Moderna, Inc. trades at $197.01 (market cap $78.65B), while Redwire Corporation trades at $9.91 (market cap $2.44B). The key difference: Moderna, Inc. is far larger — about 32.2× Redwire Corporation's market cap, and Moderna, Inc. is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Redwire Corporation for 18 Days on average.
| MRNA | RDW | |
|---|---|---|
Market Cap | $78.65B | $2.44B |
Volume | 37,373,437 | 11,053,212 |
Sector | Health | Industrials |
52-Week High | $203.46 | $25.90 |
52-Week Low | $22.36 | $5.06 |
Typical Hold Time | 59 Days | 18 Days |
Enterprise Value | $74.80B | $1.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Redwire Corporation (RDW) trades at $10.24, down 3.58% today, with bearish technical signals despite strong analyst support. The company shows robust revenue growth with $335 million in 2025 and projected $426 million in 2026, though profitability remains challenged with negative net margins. Recent Space Force contract wins and partnerships position RDW in the expanding space infrastructure market, but cash flow concerns persist with negative operating cash flow.
RDW presents a high-risk growth opportunity with 80% analyst buy ratings and a $14.88 consensus target offering 45% upside. However, persistent losses, negative cash flow, and dependence on SpaceX's Starship success create significant volatility. The stock suits aggressive investors betting on space infrastructure growth despite current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
